Annovis Bio (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company developing buntanetap for Alzheimer's and Parkinson's diseases, reported third-quarter 2026 corporate updates, highlighting progress in its pivotal Phase 3 DUET-AD trial and preparations for a planned New Drug Application. The fully enrolled trial includes 862 patients with early Alzheimer's disease and features two prespecified efficacy readouts at six and 18 months to evaluate symptomatic and disease-modifying effects, respectively. The company expects topline results from the six-month treatment period in March 2027 and plans to begin transitioning eligible patients into its Alzheimer's open-label extension study by the end of November 2026.
The timing of that readout matters because it represents one of the most closely watched near-term catalysts in neurodegenerative disease research. Alzheimer's disease affects millions worldwide, and few therapies have demonstrated meaningful disease-modifying potential. Buntanetap's mechanism, an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, aims to address underlying causes of neurodegeneration rather than only symptoms. Positive six-month data could validate this multi-target approach and open a path toward regulatory submission.
Annovis also reported enrollment of 326 patients in its Parkinson's disease open-label extension study, designed to evaluate the long-term safety and efficacy of buntanetap over 36 months. That parallel effort underscores the company's broader strategy of pursuing two major neurodegenerative indications with a single drug candidate.
In September, the company partnered with Weave Bio to support regulatory documentation and preparation of its planned NDA. Annovis subsequently closed an approximately $21 million underwritten public offering on Nov. 6, 2026, including a $5 million investment from its board chairman. Management said the financing is expected to support operations through the anticipated March 2027 topline data readout. The capital raise, combined with insider participation, signals confidence in the trial's execution and provides the runway needed to reach the data milestone without near-term financing pressure.
For investors, the March 2027 readout is the pivotal event. The DUET-AD trial's dual readouts at six and 18 months are designed to separately assess symptomatic and disease-modifying effects, a structure that could provide a richer efficacy profile than single-endpoint studies. If successful, the data would support the planned NDA and potentially reshape treatment paradigms for early Alzheimer's disease. More information about the company is available at www.annovisbio.com, and the full press release can be viewed at https://ibn.fm/6c61g. The latest news and updates relating to ANVS are available in the company's newsroom at https://ibn.fm/ANVS.
The announcement was distributed through BioMedWire, a communications platform focused on biotechnology and life sciences that is part of the Dynamic Brand Portfolio at IBN. BioMedWire reaches audiences through services including InvestorWire and editorial syndication to 5,000+ outlets, alongside social media distribution and corporate communications solutions. Full terms of use and disclaimers are available at https://www.BioMedWire.com/Disclaimer.
